IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: )
SCHERHAG et al. ) Applications
)
)
Serial No. Not Assigned )
)
Filed: )
)

For: THE USE OF ANTICOAGULANT AGENTS IN THE EXTRACORPOREAL TREATMENT OF BLOOD

PRELIMINARY AMENDMENT

Hon. Commissioner of Patents and Trademarks
Washington, D.C. 20231

Sir:

Prior to examination, kindly amend the above-identified application as follows.

IN THE CLAIMS

Please amend the claims as shown in the attached sheet.

REMARKS

The claims have been amended to eliminate multiple dependency. No new matter has been added. A clean copy of the claims is attached.

Entry of the above amendment is respectfully solicited.

Respectfully submitted,

KEIL & WEINKAUF

/HBKeil

Herbert B. Keil
Reg. No. 18,967

1101 Connecticut Ave., N.W.
Washington, D.C. 20036
(202)659-0100

AMENDED CLAIMS 4, 6, 7, 10, 11 AND 12

4. A method as claimed in claim 1 [claims 1 or 3], wherein the anticoagulant agent has a terminal half-life of at least about 4 hours.

6. A method as claimed in claim 1 [claims 1 or 3], wherein PEG-hirudin is administered.

7. A method as claimed in claim 1 [claims 1 or 3], for treating a subject with chronic renal insufficiency requiring regular hemodialysis.

10. A method as claimed in claim 8 [or 9], wherein the amount of the single dose administered for a hemodialysis is such that the APTT is prolonged about 2.7-fold to about 1.8-fold during the hemodialysis.

11. A method as claimed in claim 8 [any of claims 8 to 10], wherein the amount of the single dose administered for a hemodialysis is such that the APTT is prolonged at least about 1.2-fold until the next hemodialysis.

CLAIMS AS FILED IN THE PRELIMINARY AMENDMENT

1. A method for the prophylactic treatment of a subject whose blood has undergone extracorporeal circulation, wherein an effective amount of an anticoagulant agent is administered to said subject.

2. A method as claimed in claim 1, for the prophylaxis of vascular complications after the extracorporeal circulation.

3. A method for treating a subject with extracorporeal circulation, wherein an effective amount of an anticoagulant agent is administered to said subject for effective anticoagulant protection during the extracorporeal circulation and for prophylaxis of vascular complications after the extracorporeal circulation.

4. A method as claimed in claim 1, wherein the anticoagulant agent has a terminal half-life of at least about 4 hours.

5. A method as claimed in claim 4, wherein the anticoagulant agent has an enduring pharmacodynamic activity.

6. A method as claimed in claim 1, wherein PEG-hirudin is administered.

7. A method as claimed in claim 1, for treating a subject with chronic renal insufficiency requiring regular hemodialysis.

8. A method as claimed in claim 7, wherein the anticoagulant agent is administered in the form of a single dose per hemodialysis.

9. A method as claimed in claim 8, wherein the single dose is administered at the start of a hemodialysis.

10. A method as claimed in claim 8, wherein the amount of the single dose administered for a hemodialysis is such that the APTT is prolonged about 2.7-fold to

about 1.8-fold during the hemodialysis.

11. A method as claimed in claim 8, wherein the amount of the single dose administered for a hemodialysis is such that the APTT is prolonged at least about 1.2-fold until the next hemodialysis.